Search
Close this search box.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation® Canada

Deep Proteome and Metabolome Profiling

Collaborate with OMF CRCs in Uppsala and Melbourne to establish a global perspective.

Decode the molecular mechanisms underlying ME/CFS and contributing to specific symptoms with a particular emphasis of post-exertional malaise (PEM) through: 

  • Deep phenotyping of ME patients 
  • Global proteomic plasma profiling of ME patients
  • Global metabolomics plasma profiling of ME patients
    • Alain Moreau, PhD
    • Jonas Bergquist, MD, PhD
    • Chris Armstrong, PhD
    • Neil McGregor, BDS, MDSc, PhD
  • More than 160 samples were received and pre-treated, and cleanup steps are complete.
  • Full-scale proteomics – data ready and delivered to Montreal and Harvard for further evaluation in June 2022.
  • Manuscript in preparation.

           

STUDY HYPOTHESIS AND DESCRIPTION

A graphic illustration of red blood cells in the bloodstream.

By leveraging our expertise across Open Medicine Foundation ecosystem and through a unique partnership between three OMF Collaborative ME/CFS Research Centers (Melbourne, Montreal and Uppsala), our research team will examine the connections between molecules circulating in the blood and ME. 

This project will provide a more comprehensive understanding as to why some ME patients exhibit different symptoms and how post-exertional malaise exacerbated many symptoms. Identifying specific biomarkers will aid in the development of risk prediction of complications associated with ME, early prevention and better treatments to alleviate the most severe symptoms, which can lead eventually to new therapeutic approaches to cure ME.

No single-omic approach can completely elucidate the multitude of alterations taking place in ME. The DOMINO-ME project will couple a deep phenotyping characterization of ME patients to unbiased discovery strategies by combining global proteomic and metabolomics plasma samples profiling to uncover ME pathogenesis.